Open AccessBook
Chronic hepatitis B : an update
Naoky C. S. Tsai,Norman Gitlin +1 more
TLDR
A group of experts in this field is assembled to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice.Abstract:
A recent Institute of Medicine report has concluded that 'there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs'. It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the natural history of chronic hepatitis B with his vast knowledge and experience working with the high endemic population of Inuit in Alaska. Drs. Marc Ghany and Ed provide a very easy-to-understand description of HBV virology. Dr. Kyon-Mi Chang contributes an article on HBV immunology, which is the least understood area of this disease but has the most potential to improve our knowledge in the management of chronic hepatitis B. Dr. Anna Lok provides an authoritative review on the current issues and controversies of treatment of chronic hepatitis B. Dr. Stephen Locarnini, who has extensive experience in anti-viral resistance and its management, presents important issues in the usage of currently available anti-viral oral agents. Dr. Myron Tong discusses the current understanding of HBV carcinogenesis and updates HCC surveillance and treatment - the most dreadful outcome of this disease. Dr. Paul Martin discusses management of end- stage chronic hepatitis B - anti-viral therapy, montherapy vs combo therapy, choice of agent, when to start therapy and post-transplant patients including duration of HBIG therapy, HBcAb(+)only recipient) and Occult HBV infection. Dr. Tram Tran discusses the treatment in reproductive women, during pregnancy, and prevention of vertical transmission in third trimester with antiviral agents - an area with significant lack of good clinical evidence. Dr. Steve Han discusses management of patients with acute hepatitis B, co-infection with HDV/HCV/HIV, pre-immuno-suppressive therapy, and management of renal and heart transplant patients with HBV infection. Dr. Mei Huei Chang discusses Taiwanese success in implementing universal vaccination leading to a remarkable reduction in both prevalence of chronic hepatitis B and incidence of hepatocellular carcinoma. Finally Drs. Michelle Lai and Yun Fan Liaw provide a rundown of what we have accomplished and the hope for the future in our fight to control this disease.read more
Citations
More filters
Journal ArticleDOI
Molecular Epidemiology and Genotyping of Hepatitis B Virus of HBsAg-Positive Patients in Oman
Said Al Baqlani,Bui Tien Sy,Bui Tien Sy,Boris A. Ratsch,Khalid Al Naamani,Salah T. Al Awaidy,Suleiman Salim Al Busaidy,Georg Pauli,C.-Thomas Bock +8 more
TL;DR: The distribution of HBV genotypes, therapy resistance, and vaccine escape mutations in HBV-infected patients in Oman is shown, which will have a major impact on therapy management and diagnostics of chronic HBV infections in Oman.
Journal ArticleDOI
Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies
Satoshi Mochida,Masamitsu Nakao,Nobuaki Nakayama,Yoshihito Uchida,Sumiko Nagoshi,Akio Ido,Toshihide Mimura,Masayoshi Harigai,Hiroshi Kaneko,Hiroko Kobayashi,Tetsuya Tsuchida,Hiromichi Suzuki,Nobuyuki Ura,Yuichi Nakamura,Masami Bessho,Kazuo Dan,Shigeru Kusumoto,Yasutsuna Sasaki,Hirofumi Fujii,Fumitaka Suzuki,Kenji Ikeda,Kazuhiko Yamamoto,Hajime Takikawa,Hirohito Tsubouchi,Masashi Mizokami +24 more
TL;DR: HBV reactivation during immunosuppression was responsible for liver injuries in a quarter of the ALF/LOHF patients with persistent HBV infection, and early serum HBV-DNA monitoring may improve patient prognosis.
Journal ArticleDOI
Comparison of noninvasive models of fibrosis in chronic hepatitis B
Spiro Raftopoulos,Jacob George,Marc Bourlière,Enrico Rossi,W.B. De Boer,Gary P. Jeffrey,Gary P. Jeffrey,Max Bulsara,David J. Speers,Gerry MacQuillan,Gerry MacQuillan,Helena L. Ching,N. Kontorinis,Wendy Cheng,James Flexman,Soraya Fermoyle,Paul Rigby,Lachlan Walsh,D. Mcleod,Leon A. Adams,Leon A. Adams +20 more
TL;DR: Serum fibrosis models are predictive of fibrosis in CHB and assist in identifying subjects with low–normal ALT levels for treatment and identify subjects withLow alanine aminotransferase levels for Treatment.
Journal ArticleDOI
Antiviral therapy for chronic hepatitis B in China
TL;DR: This review will discuss some key issues in the area of antiviral treatment for chronic hepatitis B in China and the first-line antiviral agents recommended by the AASLD and EASL have not been widely used for Chinese patients.
Journal ArticleDOI
Safety of long-term nucleos(t)ide treatment in chronic hepatitis B
Ezequiel Ridruejo,Marcelo Silva +1 more
TL;DR: Although major AEs are infrequent, they can be initially clinically silent yet lead to serious medical problems, therefore, a proactive surveillance and their prompt management is recommended.